Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 15, 2020

SELL
$1.74 - $5.98 $261,000 - $897,000
-150,000 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$2.56 - $5.44 $640,000 - $1.36 Million
-250,000 Reduced 62.5%
150,000 $816,000
Q4 2018

Feb 14, 2019

SELL
$3.29 - $8.94 $575,750 - $1.56 Million
-175,000 Reduced 30.43%
400,000 $1.47 Million
Q1 2018

May 15, 2018

BUY
$7.48 - $11.53 $1.14 Million - $1.76 Million
152,400 Added 36.06%
575,000 $6.63 Million
Q3 2017

Nov 14, 2017

BUY
$11.3 - $17.23 $4.78 Million - $7.28 Million
422,600
422,600 $6.74 Million

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $401M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Rock Springs Capital Management LP Portfolio

Follow Rock Springs Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.